+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Optical Disorders Drugs Market by Prescription Type, Therapeutics, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5305572
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Optical Disorders Drugs Market grew from USD 3.14 billion in 2023 to USD 3.56 billion in 2024. It is expected to continue growing at a CAGR of 13.29%, reaching USD 7.54 billion by 2030.

The Optical Disorders Drugs market encompasses pharmaceutical treatments aimed at managing conditions such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts. These drugs are essential due to the rising prevalence of optical disorders driven by an aging global population, increased screen time, diabetes, and lifestyle changes. Their applications are primarily in therapeutic treatment, offering symptom relief, disease management, and occasionally preventive care. End-use scope includes hospitals, specialty clinics, and retail pharmacies, targeting demographics affected by visual impairments. Market growth is propelled by advancements in pharmaceutical innovations, increased awareness about eye health, and substantial investments in healthcare across emerging economies. Additionally, the demand for personalized medicine and biologics offers potential opportunities for companies to develop new, tailored drugs with fewer side effects. Emerging trends in gene therapy, artificial intelligence, and telemedicine present untapped opportunities, particularly in enhancing diagnostic precision and patient compliance. However, market growth faces challenges such as stringent regulatory frameworks, high R&D costs, and the potential for drug side effects, which can delay product launches and reduce profitability. Competition from alternative therapies, including surgical interventions and natural remedies, also poses a threat. Innovation can thrive by focusing on gene editing technologies, sustained-release drug formulations, and developing combination therapies that address multiple pathways involved in optical disorders. Companies should concentrate on collaborations with tech firms to leverage AI in drug discovery and patient management tools. The market is dynamic, with shifts towards patient-centric care models and digital health solutions. Continuous investment in R&D, along with forging partnerships for technological integrations, will be crucial for businesses aiming to capture a larger market share. Overall, the optic disorders drug market demands adaptability to rapidly changing healthcare landscapes, with strategic focus areas identified around technology adoption and targeted therapy development.

Understanding Market Dynamics in the Optical Disorders Drugs Market

The Optical Disorders Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising demand owing to increased digital exposure and unhealthy lifestyle
    • Prevalence of eye related disorders in geriatric population
    • Rise in the use of contact lenses and related disorders
  • Market Restraints
    • High treatment cost and lack of health insurance in developing economies
  • Market Opportunities
    • Technological advancements in optic drugs
    • Rising prevalence of glaucoma and an increase in healthcare expenditure
  • Market Challenges
    • Adverse health impacts of drugs

Exploring Porter’s Five Forces for the Optical Disorders Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Optical Disorders Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Optical Disorders Drugs Market

External macro-environmental factors deeply influence the performance of the Optical Disorders Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Optical Disorders Drugs Market

The Optical Disorders Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Optical Disorders Drugs Market

The Optical Disorders Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Optical Disorders Drugs Market

The Optical Disorders Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Optical Disorders Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch & Lomb Incorporated, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Kiora Pharmaceuticals, Inc., Merck & Co., Inc., Nicox SA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Optical Disorders Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Prescription Type
    • Over-The-Counter Drugs
    • Prescription Ophthalmic Drugs
  • Therapeutics
    • Age-Related Macular Degeneration
    • Conjunctivitis
    • Diabetic Macular Edema
    • Diabetic Retinopathy
    • Dry Eye
    • Eye Cancer
    • Geographic Atrophy
    • Glaucoma
    • Keratitis
    • Lens Opacification & Intraocular Lens
    • Retinal Vein Occlusion
  • End-User
    • Diagnostic Centers
    • Eye Clinics
    • Hospitals
    • Patient
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising demand owing to increased digital exposure and unhealthy lifestyle
5.1.1.2. Prevalence of eye related disorders in geriatric population
5.1.1.3. Rise in the use of contact lenses and related disorders
5.1.2. Restraints
5.1.2.1. High treatment cost and lack of health insurance in developing economies
5.1.3. Opportunities
5.1.3.1. Technological advancements in optic drugs
5.1.3.2. Rising prevalence of glaucoma and an increase in healthcare expenditure
5.1.4. Challenges
5.1.4.1. Adverse health impacts of drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Optical Disorders Drugs Market, by Prescription Type
6.1. Introduction
6.2. Over-The-Counter Drugs
6.3. Prescription Ophthalmic Drugs
7. Optical Disorders Drugs Market, by Therapeutics
7.1. Introduction
7.2. Age-Related Macular Degeneration
7.3. Conjunctivitis
7.4. Diabetic Macular Edema
7.5. Diabetic Retinopathy
7.6. Dry Eye
7.7. Eye Cancer
7.8. Geographic Atrophy
7.9. Glaucoma
7.10. Keratitis
7.11. Lens Opacification & Intraocular Lens
7.12. Retinal Vein Occlusion
8. Optical Disorders Drugs Market, by End-User
8.1. Introduction
8.2. Diagnostic Centers
8.3. Eye Clinics
8.4. Hospitals
8.5. Patient
9. Americas Optical Disorders Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Optical Disorders Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Optical Disorders Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. OPTICAL DISORDERS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. OPTICAL DISORDERS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. OPTICAL DISORDERS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. OPTICAL DISORDERS DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION & INTRAOCULAR LENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 39. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 42. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 55. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 56. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 58. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 59. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 61. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 64. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 65. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 67. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 68. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 70. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 71. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 73. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 74. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 76. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 77. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 79. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 80. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 82. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 83. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 85. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 86. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 92. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 93. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 95. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 96. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 98. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 99. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 102. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 107. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 108. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 110. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 111. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 114. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 116. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 117. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 119. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 120. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 122. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 123. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 125. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 126. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 134. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 135. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 140. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 141. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 143. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 144. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 146. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 147. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 155. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Optical Disorders Drugs Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Kiora Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information